Stop treating heterogeneous patient populations as monoliths. Leverage bfLEAP® to identify high-probability clinical responders and rescue your pipeline with precise stratification.
From Data To Discovery
Clinical data is notoriously fragmented, often locked in disparate formats across multi-omic registries, electronic health records (EHR), and historical case report forms. Our bfPREP™ module ingests and normalizes these short and wide datasets, transforming messy, real-world data into uniform, AI-ready assets without losing biological context.
Unlike traditional machine learning that merely flags superficial correlations, bfLEAP® applies advanced causal inference and customized clustering. By building interactive data networks, the platform exposes the underlying statistical dependencies and dysregulated pathways driving disease progression, separating true drivers from downstream artifacts.
bfLEAP® excels at spotting early efficacy signals and treatment success markers at the earliest phases of clinical evaluation. This allows developers to dynamically adapt trial designs, refine target selection, and continuously optimize patient cohorts.
By utilizing the bfPREP™ and bfLEAP® platforms to conduct a data-driven post-hoc analysis of a Phase III clinical trial for glufosfamide, we evaluated highly complex, multi-modal clinical data. The platform successfully bypassed the noise to uncover distinct, biologically meaningful patient clusters.
bfLEAP® identified specific patient subgroups that demonstrated an almost threefold (3x) increase in mean survival when treated with the drug compared to the control group. This actionable insight provides a clear roadmap for future patient stratification and targeted trial design.
Our core stratification capabilities are designed to transform how clinical programs approach patient selection and trial design. Through predictive biomarker discovery, we isolate complex, multi-modal molecular signatures spanning genomic, transcriptomic, proteomic, and clinical features that directly dictate how a patient will respond to a drug. By turning these insights into precise inclusion and exclusion criteria, we enable life science companies to tighten their clinical parameters. This ensures you specifically target the populations with the highest probability of success, ultimately resulting in smaller, faster, and far more cost-effective trials.
Beyond optimizing active programs, this deep-dive capability serves as a powerful engine for pipeline asset rescue. By re-analyzing data from stalled or failed trials that would otherwise be tossed, our platform can uncover hidden responder subgroups, reviving seemingly unviable therapeutic assets for highly targeted, alternative indications. This entire process is anchored by our advanced disease heterogeneity mapping, which allows researchers to untangle the nuanced biological sub-types within notoriously complex landscapes like oncology and CNS disorders. Ultimately, we help you remove the guesswork and confidently align the right biological target with the right patient population.
Request a feasibility study with our data or your own to explore what’s possible.
